News

Press Releases

December 15, 2008	FDA Approves Genzyme’s Mozobil
December 11, 2008	Progress by Genzyme, the Broad Institute and Medicines for Malaria Ventures Toward Developing Drug Candidates for Malaria Highlighted at Tropical Medicine Meeting
December 9, 2008	FDA Advisory Committee Unanimously Recommends Approval of Genzyme’s Synvisc-One
December 8, 2008	Genzyme Reports Clolar® Data Further Supporting Potential of Product to Treat Adult AML Patients
December 5, 2008	FDA Advisory Committee to Discuss Genzyme’s Synvisc-One PMA on Tuesday
November 24, 2008	Genzyme Seeks U.S. Approval for Clolar® to Treat Adult AML
November 17, 2008	Genzyme and the International Center for Genetic Engineering and Biotechnology Form Collaboration to Advance Treatments for Neglected Diseases
November 17, 2008	Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
November 4, 2008	Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products
October 22, 2008	Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif®
October 22, 2008	Genzyme Reports Strong Third-Quarter Sales and Earnings Growth
October 17, 2008	FDA Advisory Panel to Discuss Genzyme’s Myozyme BLA on Tuesday
October 15, 2008	Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
October 9, 2008	Genzyme Recognized by Scientists as a Top Employer
September 23, 2008	Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End
September 22, 2008	Genzyme Marks Grand Opening of New Science Center; Among the First Research Laboratories to Earn Gold LEED Rating
August 25, 2008	Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
August 6, 2008	Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
July 23, 2008	Genzyme Reports Strong Second-Quarter Growth
July 17, 2008	Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
June 24, 2008	Genzyme and Isis complete licensing of mipomersen
June 17, 2008	Genzyme Files Applications for Approval of Mozobil in the United States and Europe
June 2, 2008	Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
May 7, 2008	Preliminary Results from Phase 2 Genzyme Study
April 25, 2008	FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
April 23, 2008	Genzyme Reports Strong First-Quarter Growth
April 22, 2008	Genzyme to Build New R&D Center in Beijing
April 21, 2008	Genzyme Provides Update on Myozyme® Manufacturing
April 14, 2008	Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
March 19, 2008	Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 10, 2008	Genzyme Announces Presentation of New Positive Data on Carticel®
March 6, 2008	Genzyme Launches Renvela® in the U.S. for Dialysis Patients
February 13, 2008	Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
February 1, 2008	University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program
February 1, 2008	Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration
January 15, 2008	Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
January 8, 2008	Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
January 7, 2008	Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
July 23, 2007	Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases

Terms and Conditions of Use | Privacy Policy | © 2002-2009 Genzyme Corporation. All rights reserved.